Merck's adult-specific pneumococcal vaccine shows promise in late-stage study pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Results build on the data supporting the clinical profile.
Merck's V116, a 21-valent pneumococcal vaccine, exhibits strong immunogenicity and coverage in diverse adult populations. Real-world data reveal its potential to combat pneumococcal diseases effectively.